UY27378A1 - Composición farmacéutica - Google Patents

Composición farmacéutica

Info

Publication number
UY27378A1
UY27378A1 UY27378A UY27378A UY27378A1 UY 27378 A1 UY27378 A1 UY 27378A1 UY 27378 A UY27378 A UY 27378A UY 27378 A UY27378 A UY 27378A UY 27378 A1 UY27378 A1 UY 27378A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical composition
compositions
steroid
subcutaneous
administration
Prior art date
Application number
UY27378A
Other languages
English (en)
Spanish (es)
Inventor
Pierre Broqua
Martin Luck
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of UY27378A1 publication Critical patent/UY27378A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
UY27378A 2001-07-12 2002-07-11 Composición farmacéutica UY27378A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0117057.0A GB0117057D0 (en) 2001-07-12 2001-07-12 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
UY27378A1 true UY27378A1 (es) 2003-02-28

Family

ID=9918396

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27378A UY27378A1 (es) 2001-07-12 2002-07-11 Composición farmacéutica

Country Status (13)

Country Link
US (4) US20050245455A1 (enExample)
EP (1) EP1404357B1 (enExample)
JP (1) JP4845166B2 (enExample)
AR (1) AR036337A1 (enExample)
AT (1) ATE452648T1 (enExample)
DE (1) DE60234831D1 (enExample)
DK (1) DK1404357T3 (enExample)
ES (1) ES2338217T3 (enExample)
GB (1) GB0117057D0 (enExample)
MY (1) MY139203A (enExample)
PT (1) PT1404357E (enExample)
UY (1) UY27378A1 (enExample)
WO (1) WO2003006049A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
NZ538928A (en) 2002-09-27 2006-10-27 Zentaris Gmbh Administration form for pharmaceutically active peptides with sustained release of active ingredient, and method for the production thereof
EP3025722B1 (en) 2003-10-03 2020-05-27 Thorn BioScience, LLC Process for the synchronization of ovulation for timed breeding without heat detection
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
EP2120859B1 (en) * 2006-12-21 2013-11-20 Stryker Corporation Sustained-release formulations comprising bmp-7 crystals
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
PL2421545T3 (pl) 2009-04-23 2018-05-30 Jbs United Animal Health Ii Llc Sposób i kompozycja do synchronizacji czasu inseminacji
AU2010243273B2 (en) * 2009-05-01 2016-06-16 Ferring B.V. Composition for the treatment of prostate cancer
JO3550B1 (ar) * 2009-05-01 2020-07-05 Ferring Int Center Sa مركب لمعالجة سرطان البروستاتا
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
HRP20161746T1 (hr) 2010-10-27 2017-02-10 Ferring B.V. Postupak za proizvodnju degareliksa i njegovih međuprodukata
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
FI4512390T1 (fi) 2012-06-01 2025-08-01 Ferring Bv Degareliksin valmistaminen
ITMI20121638A1 (it) * 2012-10-02 2014-04-03 Marco Sbracia Utilizzo di degarelix nel trattamento dell'endometriosi e di patologie ad essa correlate
RU2015125549A (ru) 2012-11-28 2017-01-11 ДжейБиЭс Юнайтид Энимал Хэлс II ЛЛК Способ для синхронизации времени осеменения молодых свиней
US10681261B2 (en) * 2012-11-30 2020-06-09 3I Avi, Llc Inspection system
TW201625218A (zh) * 2014-04-18 2016-07-16 Ｊｂｓ聯合動物保健有限責任公司 製造含ｇｎｒｈ凝膠之方法
BR112019014192A2 (pt) * 2017-01-30 2020-02-11 Antev Limited Composição compreendendo pelo menos um antagonista de gnrh
WO2019110688A1 (en) 2017-12-05 2019-06-13 Ferring B.V. A composition comprising degarelix for use in the treatment of breast cancer
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US200486A (en) * 1878-02-19 Improvement in apparatus for attaching harness to the shafts
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ES2052488T3 (es) * 1991-04-25 1997-01-01 Romano Deghenghi Peptidos antagonistas de la hormona de liberacion de la hormona luteinizante.
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5860957A (en) * 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP2257324B1 (en) * 2008-02-11 2016-07-27 Safety Syringes, Inc. Syringe with safety needle guard and clip to prevent release of guard during reconstitution process
TWI442932B (zh) * 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
AU2010243273B2 (en) * 2009-05-01 2016-06-16 Ferring B.V. Composition for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
HRP20161746T1 (hr) * 2010-10-27 2017-02-10 Ferring B.V. Postupak za proizvodnju degareliksa i njegovih međuprodukata
EP2447276A1 (en) * 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) * 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
EP3269368A1 (en) * 2011-07-15 2018-01-17 Ferring B.V. Method for timing a colonoscopy wherein a picosulfate composition is administered

Also Published As

Publication number Publication date
WO2003006049A1 (en) 2003-01-23
JP4845166B2 (ja) 2011-12-28
ES2338217T3 (es) 2010-05-05
AR036337A1 (es) 2004-09-01
DE60234831D1 (de) 2010-02-04
US20110053846A1 (en) 2011-03-03
PT1404357E (pt) 2010-03-16
EP1404357A1 (en) 2004-04-07
JP2005511491A (ja) 2005-04-28
GB0117057D0 (en) 2001-09-05
ATE452648T1 (de) 2010-01-15
EP1404357B1 (en) 2009-12-23
DK1404357T3 (da) 2010-05-03
US20040038903A1 (en) 2004-02-26
US20050245455A1 (en) 2005-11-03
MY139203A (en) 2009-08-28
US20090018085A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
UY27378A1 (es) Composición farmacéutica
AR032556A1 (es) Medicamento de accion inmediata para el tratamiento de la disfuncion sexual
SE0100568D0 (sv) Compounds
ECSP066314A (es) Derivados piridilo y su uso como agentes terapéuticos
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
BR0108173A (pt) Composições farmacêuticas de toxina de botulina
BRPI9708706C8 (pt) composição farmacêutica para administração intravenosa a um paciente
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
CU23423B7 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
MXPA05013340A (es) Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento.
CY1105931T1 (el) Χρηση ενος αγωνιστη/ανταγωνιστη οιστρογονου για την αντιμετωπιση γυναικειας σεξουαλικης δυσλειτουργιας
AR035711A1 (es) Prodrogas 3' de 2'-desoxi-beta-l-nucleosidos; sus composiciones farmaceuticas; metodo para el tratamiento o profilaxis de una infeccion del virus de la hepatitis b y sus usos para la manufactura de composiciones farmaceuticas
ES2250416T3 (es) Estimulante de secreciohn de hormona de crecimiento.
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
BRPI0415755A (pt) antagonistas do receptor b1 de bradiquinina
ATE429925T1 (de) Methoden und pharmazeutische zusammensetzungen zur wundheilung
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
SE0100566D0 (sv) Compounds
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
ES2210727T3 (es) Composicion topica que contiene factor de crecimiento epidermico humano.
CO2023002650A2 (es) Formas farmacéuticas sólidas de palbociclib
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
CO5540279A2 (es) Formulacion liofilitada de 2-metil-tieno-benzodiazepina
EA200200801A1 (ru) Применение фолликулостимулирующего гормона (fsh) для лечения бесплодия

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150212